{
    "id": 26755,
    "fullName": "TGFB1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TGFB1 positive indicates the presence of the TGFB1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7040,
        "geneSymbol": "TGFB1",
        "terms": [
            "TGFB1",
            "CED",
            "DPD1",
            "IBDIMDE",
            "LAP",
            "TGF-beta1",
            "TGFB",
            "TGFbeta"
        ]
    },
    "variant": "positive",
    "createDate": "07/20/2017",
    "updateDate": "05/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11467,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in durable partial response in one and prolonged stable disease in three pancreatic cancer patient (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13864,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in sttable disease in a patient with appendix cancer (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 11239,
                "name": "appendix cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11466,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in complete response in one and near partial response in another patient with cervical cancer (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11465,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in complete response in 5.6% (1/18), durable partial response in 11.1% (2/18), near partial response in 5.6% (1/18), and prolonged stable disease in 27.8% (5/18) of patients with advanced solid tumors (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11468,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in prolonged stable disease in a bronchopulmonary carcinoid tumor patient (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 5410,
                "name": "pulmonary neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9078,
                    "pubMedId": null,
                    "title": "Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-?, in advanced solid tumors.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187226.html"
                },
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13862,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in partial response in a patient with anal cancer (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 14110,
                "name": "anus cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28057,
            "profileName": "TGFB1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28058,
            "profileName": "CD274 pos TGFB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}